Heated Drug Pricing Debate Fanned By Election, Teva's Olafsson Says
Executive Summary
'I can't wait until it's over,' Teva's Generic Medicines CEO Sigurdur Olafsson said of the US Presidential election; then the current debate around drug pricing will return to a discussion of value, he predicted.
You may also be interested in...
Pricing Transparency Policies Not Suited To Generics, GPhA Argues
Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.
Teva Seeds OTC Growth Synergies With Former Allergan Business
Teva's opportunity to compete in the US OTC drug market now that the Allergan's generic nonprescription products are under its roof makes company "more excited" about the space "than we have ever been," says CEO Sigurdur Olaf Olaffson,
Teva Seeds OTC Growth Synergies With Former Allergan Business
Teva's opportunity to compete in the US OTC drug market now that the Allergan's generic nonprescription products are under its roof makes company "more excited" about the space "than we have ever been," says CEO Sigurdur Olaf Olaffson,